
We need policies that make digital therapeutics accessible and acceptable to a broad patient audience. What barriers are there to reaching that goal?
Dr Carl is vice president of clinical development & medical affairs at Big Health Inc.
We need policies that make digital therapeutics accessible and acceptable to a broad patient audience. What barriers are there to reaching that goal?